Monopar Therapeutics
MNPR
13 hedge funds and large institutions have $484K invested in Monopar Therapeutics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
8% more funds holding
Funds holding: 12 → 13 (+1)
0.01% more ownership
Funds ownership: 0.32% → 0.33% (+0.01%)
9% less capital invested
Capital invested by funds: $533K → $484K (-$49.2K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$37.2K |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$385 |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$23 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$25.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.69K |
| 3 |
FCA
FinTrust Capital Advisors
Greenville,
South Carolina
|
-$1K |
| 4 |
Morgan Stanley
New York
|
-$11 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $230K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $85K | – | – | – |
|
3
Northern Trust
Chicago,
Illinois
| $81K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $45K | +$37.2K | +3,291 | +530% |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| $13K | – | – | – |
|
|
6
Morgan Stanley
New York
| $9K | -$11 | -1 | -0.1% |
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $9K | – | – | – |
|
|
8
BlackRock
New York
| $5K | -$25.8K | -2,278 | -83% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $5K | -$2.69K | -238 | -33% |
|
|
APA
10
American Portfolios Advisors
Holbrook,
New York
| $1.61K | – | – | – |
|
|
FCA
11
FinTrust Capital Advisors
Greenville,
South Carolina
| – | -$1K | -100 | Closed |
|
|
12
Wells Fargo
San Francisco,
California
| – | +$11 | +1 | +20% |
|
|
13
Fidelity Investments
Boston,
Massachusetts
| – | +$23 | +2 | New |
|
|
14
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | +$385 | +34 | New |
|
MNPR Hedge Fund Activity: Q2 2022 in Review
13 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q2 2022, worth a combined $484K — down 9.2% from $533K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new MNPR positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was UBS Group, adding an estimated $37.2K. The largest seller was BlackRock, cutting an estimated $25.8K.
- 13 institutional investors held Monopar Therapeutics (MNPR) as of Q2 2022, up from 12 in Q1 2022.
- Funds reported $484K of Monopar Therapeutics stock for Q2 2022, down 9.2% quarter-over-quarter.
- 2 funds opened new Monopar Therapeutics positions in Q2 2022 and 1 closed out, a net change of +1 holder.
- The largest Monopar Therapeutics buyer in Q2 2022 was UBS Group, an estimated $37.2K added.
- The largest Monopar Therapeutics seller in Q2 2022 was BlackRock, an estimated $25.8K sold.
Based on aggregated 13F filings for Q2 2022.